Stoke Therapeutics Jobs & Careers

Bedford

Website LinkedIn Twitter / X

Founded: 2014
Employees: 175
Total Funding: $360.1M

Biotechnology Health Care Pharmaceutical Therapeutics

Founded by Adrian Krainer, Edward Kaye, Huw Nash, Isabel Aznarez in 2014.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels...